Adapthealth CORP

AdaptHealth Corp. announced its second quarter 2026 financial results, reporting a net loss and lowering its full-year outlook, while also detailing the divestiture of its Diabetes Health business.

AdaptHealth Corp. has entered into a definitive agreement to divest its Diabetes Health business to Cardinal Health for $235 million in cash.

AdaptHealth Corp. has disclosed a material cybersecurity incident involving unauthorized access to its systems and exfiltration of patient data, including passwords for insurance billing.

AdaptHealth Corp. announced its first quarter 2026 financial results, highlighting a significant de novo expansion and a $1.1 billion refinancing, alongside the departure of its Chief Operating Officer.

AdaptHealth Corp. has closed a $1.1 billion senior secured credit facility, extending its debt maturity and reducing borrowing costs.

AdaptHealth Corp. announced its fourth quarter and full-year 2025 financial results, including a net loss, alongside positive operational growth and robust 2026 financial guidance.

AdaptHealth Corp. reported a 5.4% increase in net revenue for Q1 2026, reaching $819.8 million, but experienced a wider net loss of $16.0 million compared to the prior year.

AdaptHealth Corp. reported a 1.8% increase in Q3 2025 net revenue to $820.3 million, alongside significant debt reduction and an agreement in principle to settle a class action lawsuit.

AdaptHealth Corp. reported a decrease in net revenue and net income for Q2 2025, despite a significant gain from business dispositions, while grappling with persistent internal control weaknesses and multiple legal proceedings.

AdaptHealth Corp. reports a decrease in net revenue for Q1 2025, impacted by shifts in the diabetes segment and ongoing legal investigations, despite growth in the respiratory health segment.

AdaptHealth Corp. experienced a slight revenue increase in Q3 2024, offset by a goodwill impairment and ongoing legal settlements, impacting overall profitability.

AdaptHealth Corp. saw a slight revenue increase in Q2 2024, but faced challenges in its diabetes segment and incurred significant expenses related to legal settlements.

AdaptHealth Corp. reported a net loss of $70.8 million for the fiscal year ended December 31, 2025, driven by a goodwill impairment charge and a slight revenue decrease.

AdaptHealth Corp. has filed an Amendment No. 1 to its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, solely to include the previously omitted Equity Compensation Plan Table.

AdaptHealth Corp.'s 2024 10-K filing reveals a complex financial landscape, marked by revenue growth tempered by rising costs, regulatory challenges, and ongoing efforts to bolster internal controls.

AdaptHealth Corp.'s 10-K filing outlines stockholder rights, authorized stock, and compliance with regulations, including cybersecurity and healthcare laws.

AdaptHealth Corp. Chief Commercial Officer Russell E. Schuster III has sold 11,275 shares of common stock for $10.44 per share, executed automatically under a pre-established Rule 10b5-1 trading plan.

AdaptHealth Corp. director David Solomon Williams III reported the acquisition of 18,999 restricted stock units on June 24, 2026.

AdaptHealth Corp. director Susan T. Weaver reported the acquisition of 18,999 common stock shares, valued at $0, and now beneficially owns 73,472 shares.

AdaptHealth Corp. director Gregory Belinfanti acquired 18,999 shares of common stock through restricted stock units.

Bradley J. Coppens, a Director at AdaptHealth Corp., reported transactions involving common stock and restricted stock units.

AdaptHealth Corp. reports a transaction where Director Theodore B. Lundberg acquired 18,999 shares of common stock.

AdaptHealth Corp. announces its 2026 Annual Meeting of Stockholders to be held virtually on June 18, 2026, detailing proposals for director elections, auditor ratification, and executive compensation review.

AdaptHealth Corp. will hold its Annual Meeting of Stockholders on June 18, 2025, to elect directors, ratify the appointment of KPMG LLP, and conduct a say-on-pay vote.

AdaptHealth Corp. is soliciting proxies for its 2024 Annual Meeting of Stockholders to vote on proposals including declassifying the board of directors, officer exculpation, and amendments to the stock incentive plan.

One Equity Partners and its affiliates have filed an Amendment No. 4 to Schedule 13D, disclosing a continued beneficial ownership of 11.7% in AdaptHealth Corp. common stock.

Dimensional Fund Advisors LP has disclosed beneficial ownership of 6,920,973 shares, representing 5.1% of AdaptHealth Corp's common stock, as of March 31, 2026.

The Vanguard Group has filed an amended Schedule 13G, reporting 0% beneficial ownership in AdaptHealth Corp. following an internal realignment.

FMR LLC and Abigail P. Johnson have reported a 5.6% beneficial ownership stake in AdaptHealth Corp, totaling over 7.6 million shares.

Deerfield Management and affiliated funds disclose beneficial ownership of 8.48% of AdaptHealth Corp.'s Class A Common Stock, including convertible preferred shares.

The Vanguard Group has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 8.33% in AdaptHealth Corp common stock.

FMR LLC and Abigail P. Johnson have reported a 6.7% beneficial ownership stake in AdaptHealth Corp's common stock as of June 30, 2025.